Search for a clinical trial
Other search option(s)
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
- Type of clinical trial : Drug clinical trial
- Recruiting project : Yes
- Status : Ongoing trial
- Funding body(ies) :
- Geographic coverage : Global
- Sponsor : Celgene corporation
- Website
- Phase : I
Download document
Principal investigator of clinical trial
- INFORMATION NOT PROVIDED
- Charité - Universitätsmedizin Berlin
- Charitéplatz 1
- 10117 BERLIN
- GERMANY
- More information
- Phone : 49 (0)30 450 50
- Fax : -
- Website
Principal investigator of clinical trial
- INFORMATION NOT PROVIDED
- Universitätsklinikum Münster
- Albert-Schweitzer-Campus 1
- 48149 MÜNSTER
- GERMANY
- More information
- Phone : 49 (0)251 83 48001
- Fax : -
- Website
Principal investigator of clinical trial
- INFORMATION NOT PROVIDED
- Universität Leipzig
- Ritterstraße 26
- 04109 LEIPZIG
- GERMANY
- More information
- Phone : 49 (0)341 97 108
- Fax : 49 (0)341 97 30099
- Website
Principal investigator of clinical trial
- INFORMATION NOT PROVIDED
- Universitätsklinikum Würzburg
- Josef-Schneider-Str. 2
- 97080 WÜRZBURG
- GERMANY
- More information
- Phone : 0049 931 2010
- Fax : -
Sponsor of clinical trial
- CELGENE CORPORATION
- Celgene Corporation
- 86 Morris avenue
- SUMMIT NJ 07901
- UNITED STATES
- More information
- Phone : 190 86 73 90 00
- Fax : -
Last update: October 2021
Additional information
Further information on this research
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.